Multi-cohort validation: A comprehensive exploration of prognostic marker in clear cell renal cell carcinoma
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112300 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Yifei Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzh…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Abstract (Originalsprache)
Clear cell renal cell carcinoma (ccRCC) is the most common form of RCC. It is characterized by resistance to traditional radiotherapy and chemotherapy, as well as an unfavorable clinical prognosis. Although TYMP is implicated in the advancement of tumor progression, the role of TYMP in ccRCC is still not understood. Heightened TYMP expression was identified in ccRCC through database mining and confirmed in RCC cell lines. Indeed, TYMP knockdown impacted RCC cell proliferation, migration, and invasion in vitro. TYMP showed a positive correlation with clinicopathological parameters (histological grade, pathological stage). Moreover, patients with high TYMP expression were indicative of poor prognosis in TCGA-ccRCC and external cohorts. The results of single-cell analysis showed that the distribution of TYMP was predominantly observed in monocytes and macrophages. Furthermore, there is a significant association between TYMP and immune status. Methylation analysis further elucidated the relationship between TYMP expression and multiple methylation sites. Drug sensitivity analysis unveiled potential pharmaceutical options. Additionally, mutation analyses identified an association between TYMP and the ccRCC driver genes like BAP1 and ROS1. In summary, TYMP may serve as a reliable prognostic indicator for ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
- Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
- Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. Electronic address: xuziqiang@wzhospital.cn.
Zitieren
APA
Li, Y., Fan, C., Hu, Y., Zhang, W., Li, H., Wang, Y., & Xu, Z. (2024). Multi-cohort validation: A comprehensive exploration of prognostic marker in clear cell renal cell carcinoma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112300
Vancouver
Li Y, Fan C, Hu Y, Zhang W, Li H, Wang Y, et al. Multi-cohort validation: A comprehensive exploration of prognostic marker in clear cell renal cell carcinoma. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112300
BibTeX
@article{Li2024,
author = {Li, Yifei and Fan, Congcong and Hu, Yuhang and Zhang, Weizhi and Li, Hang and Wang, Yining and Xu, Ziqiang},
title = {Multi-cohort validation: A comprehensive exploration of prognostic marker in clear cell renal cell carcinoma},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112300}
}
EUVIMED